- Location
castration resistant prostate cancer
"-
The Company's Robust Performance Was Driven by New and Existing Drug Sales
Apr 16, 2014The common stock of healthcare and medical device giant Johnson & Johnson (JNJ) soared to recent highs following the company's announcement of first quarter results that beat analysts' estimates. The company's robust performance was ...
Tags: Health, Medicine, medical device
-
Bayer Healthcare Has Received Marketing Authorization From The European Commission
Nov 19, 2013Bayer HealthCare has received marketing authorization from the European Commission (EC) for its Xofigo injection for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral ...
-
US-Based Johnson & Johnson Has Agreed to Buy Aragon Pharmaceuticals for $1bn
Jun 19, 2013US-based Johnson & Johnson has agreed to buy Aragon Pharmaceuticals, a discovery and development company focused on drugs to treat hormonally-driven cancers, for nearly $1bn. As per the acquisition agreeement, an upfront cash payment of ...
Tags: Johnson&Johnson, Medicine
-
Astellas Pharma and Medivation Have Announced The Health Canada Approval of Xtandi
Jun 4, 2013Astellas Pharma and Medivation have announced the Health Canada approval of Xtandi (enzalutamide) capsules to treat metastatic castration-resistant prostate cancer. The oral, once-daily androgen receptor inhibitor is indicated for ...
Tags: Astellas Pharma, Medicine
-
Astellas Pharma and Medivation Have Announced The Submission of Application
May 27, 2013Astellas Pharma and Medivation have announced the submission of application for marketing approval of enzalutamide in Japan for the treatment of prostate cancer. The application was filed by Astellas with the Ministry of Health, Labour ...
Tags: Astellas, Marketing Application
-
FDA Has Approved Algeta's Xofigo Injection for The Treatment of Patients
May 21, 2013The US FDA has approved Algeta's Xofigo (radium-223 dichloride) injection for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. Xofigo is the first ...
-
US FDA Has Approved Xofigo for The Treatment of Symptomatic Prostate Cancer Therapy
May 17, 2013The US FDA has approved Xofigo (radium Ra 223 dichloride) for the treatment of symptomatic late-stage (metastatic) castration-resistant prostate cancer spread to bones but not to other organs in men. The therapy is indicated for men whose ...
-
EC Has Approved Broader Indication of Janssen-Cilag International's Oral
Jan 15, 2013The European Commission (EC) has approved broader indication of Janssen-Cilag International's oral, once-daily medication Zytiga (abiraterone acetate). Licence extension includes the use of Zytiga as a combination therapy along with ...
Tags: Zytiga, Janssen Europe, medical
-
Medivation and Astellas Pharma Have Announced FDA Approval
Dec 14, 2012Medivation and Astellas Pharma have announced FDA approval for Xtandi (enzalutamide) capsules to treat metastatic castration-resistant prostate cancer in patients with previously received docetaxel. Medivation and Astellas expect to make ...
Tags: Medivation, Astellas, FDA
-
mCRPC Has Won FDA Approval for Use in Patients Who Have Not Received Chemotherapy
Dec 11, 2012Janssen's Zytiga indicated for metastatic castration-resistant prostate cancer(mCRPC),has won FDA approval for use in patients who have not received chemotherapy. The oral,once-daily medication was previously used in combination with ...
-
Tokai Pharmaceuticals Has Gained FDA Fast Track Designation for Galeterone
Dec 6, 2012Tokai Pharmaceuticals has gained FDA fast track designation for galeterone (TOK-001) for the potential treatment of metastatic castration-resistant prostate cancer (CRPC). Galeterone disrupts androgen receptor (AR) signaling, the key ...
Tags: galeterone, TOK-001, castration-resistant prostate cancer, CRPC
-
Xtandi Is Being Distributed Through a Network of Specialty Pharmacies and Distributors
Nov 30, 2012Medivation and Astellas Pharma have launched Xtandi (enzalutamide) capsules for patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. Xtandi, an oral, once-daily androgen receptor inhibitor ...
-
Janssen Research and Development Has Received The Priority Review
Aug 30, 2012Janssen Research and Development has received the Priority Review for the supplemental New Drug Application (sNDA) for ZYTIGA from US Food and Drug Administration (FDA). Zytiga (abiraterone acetate) is administered in combination with ...
Tags: sNDA, priority review, FDA
-
MAA for Enzalutamide is Submitted to EMA by Astellas
Jun 27, 2012Astellas Pharma and Medivation have announced the submission of marketing authorization application (MAA) to the European Medicines Agency (EMA) for enzalutamide to treat metastatic castration-resistant prostate cancer in men who have ...
Tags: enzalutamide, metastatic castration-resistant prostate cancer
-
Janssen Research Submitted a Supplemental New Drug Application to FDA for Zytiga
Jun 18, 2012Janssen Research & Development has announced that it has submitted a supplemental New Drug Application to FDA for ZYTIGA(abiraterone acetate). Janssen-Cilag International NV has also sent a type II variation to the European Medicines ...
